Tag: Europe
-
“Dark Genome” Drug Discoverer Gains $37M in Early Funds
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University of Oxford medical school. Nucleome Therapeutics is seeking new treatments for…
-
Drug Licensed for Precision Autism Spectrum Therapies
A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress.
-
Nasal Spray Vaccines Get CEPI, NIH Funding
A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea.
-
Patent Issued for Crispr-Edited Viruses in Microbiome
A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments.
-
Eye Disease Gene-Therapy Biotech Adds Venture Funds
A biotechnology company designing treatments for inherited eye diseases with Crispr gene editing is raising €75 million in venture financing.
-
Gut Microbes Shown to Detect Colorectal Cancer
An analysis of gut bacteria and blood samples from patients indicates changes in the microbiome can provide early warnings for colorectal cancer.
-
Trial Shows LSD Treatment Reduces Anxiety Symptoms
A clinical trial shows a medication made with lysergic acid diethylamide or LSD, given in a supervised clinical setting, helps reduce anxiety and depression symptoms.
-
Patent Issued for Anti-Bacterial Viruses with Crispr Payloads
A biotechnology company received a patent for its engineered viruses to deliver gene-edited treatments to combat bacterial infections in the microbiome.
-
Women’s Health Companies Partner on New Contraceptive
Two companies working in women’s reproductive health are developing a new non-hormonal contraceptive that works in cervical mucous membranes.
-
AI Analytics Find New ALS Genetic Drug Targets
Researchers analyzed medical and scientific databases with algorithms to identify eight previously unreported biomarkers contributing to neurodegeneration similar to ALS.